Learn More
OBJECTIVE The aim of this study was to determine the optimal patient-reported outcome measure (PROM) for assessing symptom benefit in trials of palliative chemotherapy for women with symptomatic(More)
4003 Background: REG is an oral multi-kinase inhibitor warranting evaluation in AOGC following failure of 1st or 2nd line chemotherapy (CT) where few options exist. Methods: International (Australia(More)
Chemotherapy for platinum-resistant/refractory ovarian cancer is motivated by the hope of benefit. We sought to determine the relationships between: (a) trait hope, expectation of symptom benefit(More)